Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor-infiltrating lymphocytes (Senlang Bio)
- Development stage
- Unknown
- Lead developer
- Avalon GloboCare
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
This autologous tumor-infiltrating lymphocyte (TIL) therapy is a cell-based biologic being developed by Hebei Senlang Biotechnology (a subsidiary of Avalon GloboCare) for the treatment of advanced glioblastoma multiforme. The therapeutic process involves the surgical extraction of a patient's own tumor-resident lymphocytes, which are then expanded to large numbers ex vivo. Following a lymphodepletion chemotherapy regimen to create a favorable environment for the cells, the expanded TILs are reinfused into the patient. These lymphocytes are naturally primed to recognize a broad spectrum of patient-specific tumor antigens, enabling a targeted immune response against the malignancy. The therapy is currently being evaluated in Phase 1 clinical trials to assess its safety and preliminary efficacy in adults with malignant glioblastoma.
- Other names
- TIL therapyautologous TILstumor-infiltrating lymphocytes
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on autologous tumor-infiltrating lymphocytes (Senlang Bio).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor-infiltrating lymphocytes (Senlang Bio).